Treatment Trials

5 Clinical Trials for Various Conditions

Focus your search

SUSPENDED
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Description

The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.

ACTIVE_NOT_RECRUITING
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
Description

The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.

WITHDRAWN
Castleman Disease Collaborative Network Biobank
Description

The purpose of this study is to create a biobank, which collects, stores, and distributes samples of human tissues, blood, and related health information to qualified scientists, in order to help doctors and researchers better understand why Castleman Disease occurs and develop ways to better treat and prevent it.

COMPLETED
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Description

Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction. In this study, we will investigate inflammatory markers, cells, and signaling pathways in prospectively collected blood samples and/or buccal swabs or saliva using biochemical and RT-PCR techniques, proteomics, genomics, immunohistochemistry, storage for future use, cell culture treated with external stimuli, flow cytometry, and other molecular tests

RECRUITING
International Registry for Patients With Castleman Disease
Description

The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease.